BOSTON, Mass. ( TheStreet) -- A calendar of important, potentially stock-moving biotech events for August:

Aug. 8
Alexza Pharmaceuticals ( ALXA) resubmission of AZ-004 new drug application to FDA.

Aug. 10
FDA approval decision for Gilead Sciences' ( GILD) HIV drug Btripla. Aug. 20
FDA approval decision for Regeneron Pharmaceuticals ( REGN) Eyelea for wet age-related macular degeneration.

Aug. 28
FDA approval decision for Dendreon's ( DNDN) Provenge manufacturing facility in Atlanta. Dendreon reports second-quarter results on Aug. 3.

Aug. 29
FDA approval decision for Nupathe ( PATH) migraine patch Zelrix.

Aug. 30
FDA approval decision for Seattle Genetics' ( SGEN) lymphoma drug Adcetris.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to http://twitter.com/adamfeuerstein.

>To submit a news tip, send an email to: tips@thestreet.com.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Teva (TEVA) Acquires NuPathe (PATH) for $144 Million

NuPathe Picks Teva as Merger Partner

Why NuPathe Inc. (PATH) Is Up Today

Nupathe's Failure to Launch Leads to Modest Takeover

5 Stocks Under $10 Set to Soar